Lanadelumab for Treatment of COVID-19 Disease

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

43

Participants

Timeline

Start Date

October 30, 2020

Primary Completion Date

February 25, 2021

Study Completion Date

April 30, 2021

Conditions
COVID-19
Interventions
BIOLOGICAL

lanadelumab

single dose, or two doses administered iv

OTHER

regular care

no lanadelumab administration, treated according to regular care

Trial Locations (4)

Unknown

Amsterdam UMC, Amsterdam

Rijnstate hospital, Arnhem

Radboudumc, Nijmegen

UMC Utrecht, Utrecht

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Takeda

INDUSTRY

lead

Radboud University Medical Center

OTHER